About In Vitro Diagnostic Development

At the beginning of the establishment in 2006, SCI had previously consisted of two divisions: Stem Cell and Cancer Research. Both divisions had produce qualified research publications as well as generating commercializable products. Over time, as a response to the pandemic situation, in 2020, SCI expanded its area of research to include infectious diseases and developed saliva-based COVID-19 RT-PCR kit. In 2021, henceforward, Cancer Research Division changed its name to In Vitro Diagnostic (IVD) Division to address unmet medical needs and facilitate the new drug development.